Baker McKenzie Switzerland has appointed Dr. Valentina Hirsiger (pictured) as a new partner as of 1 July 2024. In her new role, Hirsiger will strengthen Baker McKenzie’s competence in the areas of Dispute Resolution, International Arbitration,
Tags :dx2
Bär & Karrer advised investor Coatue in an oversubscribed USD 10.7 million seed financing round for DeepJudge, advised by Wenger Vieli. The round also saw participation from several angel investors such as Gokul Rajaram and
Advestra advised Novartis on the issuance of CHF 2.2 billion bonds, placed in five tranches as follows: UBS, BNP Paribas (Suisse) and Deutsche Bank Aktiengesellschaft acted as joint lead managers
WalderWyss advised Klar on Bühlmann’s all shares acquisition. Vischer provided legal and tax advice to Dr. Roland P. Bühlmann and Marie-Thérèse Bühlmann in this transaction. Located in Schönenbuch (
MLL in collaboration with Oberhammer Rechtsanwälte advised Mirus Software, a Swiss provider of software solutions in the hospitality industry, which is part of the Austrian group Alpha VCX active in IT and software businesses,
ISS Facility Services, advised by CMS, acquired gammaRenax, advised by Vischer. With the acquisition, ISS seeks to strengthen its position as a provider of comprehensive facility management services in Switzerland. CMS’ team Corporate / M&
Baker McKenzie advised La Collective de Prévoyance – COPRE (“COPRE”) on the sale of a residential complex in Nyon. Baker McKenzie advised COPRE on all legal and tax aspects of the transaction, with a team
Stéphanie Fougou (pictured) is the new president of the European Company Lawyers Association (ECLA). Never before, in its 41-year history, has ECLA been chaired by a woman. Stéphanie Fougou and ECLA Fougou is
Wenger Vieli advised Alturos Destinations, a provider of tourism technology solutions, on all Swiss legal and tax matters during the sale to Juniper Group. The funds will support Alturos’ growth and expand its international market
Boris Zaïtra (pictured), currently head of group business development, will be appointed as head of corporate business development, effective 1 july 2024. James Sabry, head of Roche Pharma Partnering, will be retiring after fourteen years in
